Core Viewpoint - The company has approved several key resolutions during its board meeting, including the government acquisition of idle assets and the establishment of a high-end formulation production and R&D base, which are aimed at optimizing asset structure and enhancing operational efficiency [1][2][3][4][6][10]. Group 1: Government Acquisition of Idle Assets - The board approved the acquisition of idle assets from the Lanzhou Biological Pharmaceutical Factory and Lanzhou Zhongmu Pharmaceutical Technology Co., Ltd. by the Lanzhou Chengguan District People's Government, with a total compensation amount of 228.9782 million yuan [2][10][12]. - The assets being acquired include state-owned land, buildings, and equipment located at No. 2 Yanchang Road, Chengguan District, Lanzhou, which have been assessed as idle [10][12][32]. - The compensation amount is based on an evaluation report from Gansu Fangjia Real Estate Asset Appraisal Co., Ltd., with the land and buildings valued at 218.1045 million yuan and equipment at 10.8737 million yuan [12][20]. Group 2: High-end Formulation Production and R&D Base - The board approved the implementation of a high-end formulation production and R&D base project by its wholly-owned subsidiary, Zhongmu Nanjing Animal Pharmaceutical Co., Ltd., with a total planned investment of 299.6186 million yuan [3][6]. - The funding for the project will come from the subsidiary's own funds and self-raised funds, aimed at enhancing the company's product structure and promoting the development of its pet business [3][6]. Group 3: Governance and Management Updates - The board approved the revision of the Comprehensive Budget Management Measures, which aims to improve the company's financial management practices [4][5]. - The board also agreed to adjust the Strategic Committee to include ESG (Environmental, Social, and Governance) responsibilities, enhancing the company's governance structure and commitment to sustainable development [6][7]. - A new Market Value Management System was also approved to better manage the company's market capitalization [7].

Core Viewpoint - The company has received approval from the Ministry of Agriculture and Rural Affairs for its subsidiary to register two new veterinary drugs for dogs and cats, indicating a significant advancement in its product offerings [1] Group 1 - The company, Blue Biological (603739), announced that its wholly-owned subsidiary, Qingdao Kangdian Animal Pharmaceutical Co., Ltd., has successfully applied for the registration of "Fluralaner Drops (for Dogs)" and "Fluralaner Drops (for Cats)" as Class II new veterinary drugs [1] - The Ministry of Agriculture and Rural Affairs has issued the "New Veterinary Drug Registration Certificate" for these products, which marks a key milestone in the company's development strategy [1]